A new study published in the NEJM Evidence with Seidman University Hospital

CLEVELAND – Data from a new study published in NEJM notes shows promise for short-term personalized ADT use in men with predominant intermediate-risk prostate cancer. The study involved ArteraAI, a developer of multimodal artificial intelligence-based predictive and prognostic cancer tests, and other researchers including University Hospitals (UH) Seidman Cancer Center. This information validates the first predictive AI biomarker benefit of androgen deprivation therapy (ADT) in prostate cancer.

“This is truly a milestone in the treatment of prostate cancer,” said Daniel Spratt, MD, first author of the study. Spratt is the Vincent K. Smith Chair in Radiation Oncology and Professor in the Department of Radiation Oncology at the UH Seidman Cancer Center and Case Western Reserve University. He is also a member of the Case Comprehensive Cancer Center. “With the first biomarker predictive of ADT benefit in prostate cancer, made with AI, we can further realize the ability to create personalized approaches to cancer treatment. It is an honor to lead this work in collaboration with NRG Oncology, Artera AI, and dozens of research colleagues. We are fortunate to have offered this test here at the UH Seidman Cancer Center to our patients from Northeast Ohio, our state, and around the world.”

This study used a new deep learning methodology and histopathological image data from more than 5,000 patients across five Phase 3 randomized trials, with long-term follow-up. Patients in this trial were enrolled from more than 100 centers across the US and Canada. The predictive AI biomarkers were developed using a data set consisting of approximately 20% of African American patients. In previous US-based clinical trials, African-American men made up only 10.8% of prostate cancer trial participants.

Daniel I. Simon, MD, University Hospitals President, Academic & External Affairs and Chief Scientific Officer, and Ernie and Patti Novak Distinguished Chair in Healthcare Leadership said, “We are committed to impactful research that impacts patient outcomes in positive ways and this research exemplifies UH’s vision of health science and the compassionate art that our doctors strive for every day.”

Theodoros Teknos, MD, President, and Scientific Director, UH Seidman Cancer Center and the Jane and Lee Seidman Chair in Cancer Innovation echo those thoughts., “This AI-enabled invention perfectly illustrates the UH-Seidman Cancer Center’s national leadership in scientific excellence and innovation. We applaud this important contribution to the treatment of prostate cancer.”

In patients with localized prostate cancer, ADT may be added to radiotherapy if better patient outcomes are anticipated. However, ADT is also known to have negative side effects ranging from loss of sexual function to potentially detrimental effects on heart and brain health. Several studies have shown that many men do not need ADT as part of their treatment plan, and that radiotherapy alone is effective. Given the opportunity to utilize biomarkers, most patients at intermediate risk could potentially avoid the morbidity and financial burden associated with ADT.

Gary Schwartz, MD, Director of the Case Comprehensive Cancer Center said, “The Case Comprehensive Case Center (Case CCC) commends the leadership provided by Dr. Spratt in conducting a seminal study on the use of AI technology to predict the male population with localized prostate. cancer would benefit most from adding ADT therapy to radiotherapy. This discovery will be a change in practice and will have a profound impact on the way we approach the treatment of this disease. This work describes the leadership provided by Case CCC members in the treatment and advancement of cancer treatment in the United States. The fact that this study included a high percentage of African Americans, a patient population at very high risk of developing prostate cancer, also demonstrates the impact these results may have on an underrepresented minority population in the United States.

###

About University Hospital / Cleveland, Ohio
Founded in 1866, University Hospital serves the needs of patients through an integrated network of 21 hospitals (including five joint ventures), more than 50 medical centers and outpatient facilities, and more than 200 physician offices in 16 counties throughout northern Ohio. The system’s flagship quaternary care, academic medical center, University Hospitals Cleveland Medical Center, affiliated with Case Western Reserve University School of Medicine, Northeast Ohio Medical University, Oxford University, Technion Israel Institute of Technology and . National Taiwan University School of Medicine. The main campus also includes UH Rainbow Babies & Children’s Hospital, ranked among the best children’s hospitals in the country; UH MacDonald Women’s Hospital, the only women’s hospital in Ohio; and the UH Seidman Cancer Center, part of the NCI-designated Comprehensive Case Cancer Center. UH is home to some of the most prestigious clinical and research programs in the country, with more than 3,000 active clinical trials and ongoing research studies. UH Cleveland Medical Center is consistently among the top performers in national ranking surveys, including “America’s Best Hospital” from US News & World Report. UH is also home to 19 Clinical Care Delivery and Research Institutes. UH is one of Northeast Ohio’s largest employers with more than 30,000 employees. Follow UH on LinkedIn, Facebook And Twitter. For more information, visit UHhospitals.org.